

CITATION REPORT

List of articles citing

Intravitreal bevacizumab for retinopathy of prematurity: refractive error results

DOI: 10.1016/j.ajo.2013.01.014

American Journal of Ophthalmology, 2013, 155, 1119-1124.e1.

Source: <https://exaly.com/paper-pdf/55110876/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
107	[Childhood retinal detachment: ROP and myopia]. 2013 , 230, 894-901		0
106	Insulin-like growth factor-1 and anti-vascular endothelial growth factor in retinopathy of prematurity: has the time come?. 2014 , 106, 254-60		16
105	Long term refractive and structural outcome following laser treatment for zone 1 aggressive posterior retinopathy of prematurity. 2014 , 7, 116-9		21
104	Intravitreal Bevacizumab in Retinopathy of Prematurity: Inject or Not?. 2014 , 3, 368-78		7
103	Retinopathy of prematurity. 2014 , 61, 567-77		4
102	Pathologic Myopia. 2014 ,		30
101	Intravitreal low-dosage bevacizumab for retinopathy of prematurity. 2014 , 92, 577-81		41
100	Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes. 2014 , 28, 1080-6; quiz 1087		46
99	Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. 2015 , 35, 667-74		85
98	Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy. 2015 , 234, 211-7		24
97	A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity. 2015 , 10, e0129383		51
96	Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser. 2015 , 19, 140-4		35
95	Retinopathy of prematurity: recent developments in diagnosis and treatment. 2015 , 10, 167-182		5
94	Refractive status of Chinese with laser-treated retinopathy of prematurity. 2015 , 92, S3-9		15
93	Review of the latest treatments for retinopathy of prematurity: laser photo-ablation versus intravitreal anti-VEGF agents in the management of high-risk pre-threshold (type 1) disease. 2015 , 10, 421-430		1
92	Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey. 2015 , 253, 1677-83		45
91	Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity. 2015 , 53, 15-20		44

90	Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. 2015 , 40, 585-91	32
89	Review of effects of anti-VEGF treatment on refractive error. 2016 , 8, 135-140	17
88	Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity. 2016 , 10, 1323-7	9
87	Intravitreal bevacizumab for retinopathy of prematurity in infants ineligible for laser therapy. 2016 , 46, 764-8	
86	Evaluation of Refractive Errors and Ocular Biometric Outcomes after Intravitreal Bevacizumab for Retinopathy of Prematurity. 2016 , 24, 84-8	15
85	Nanoparticles for Ocular Drug Delivery. 2016 , 197-223	1
84	Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy. 2016 , 6, 27082	25
83	Refractive outcomes following the treatment of retinopathy of prematurity in the anti-VEGF era: a literature review. 2016 , 20, 539-540.e3	7
82	Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy. 2016 , 123, 1845-55	98
81	Long-term intraocular pressure changes after intravitreal injection of bevacizumab. 2016 , 35, 310-4	19
80	Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity. 2016 , 31, 163-8	19
79	Visual outcome and refractive status in first 3 years of age in preterm infants suffered from laser-treated Type 1 retinopathy of prematurity (ROP): a 6-year retrospective review in a tertiary centre in Hong Kong. 2018 , 38, 163-169	4
78	Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children. 2017 , 42, 1054-1058	20
77	BRUCH MEMBRANE AND THE MECHANISM OF MYOPIZATION: A New Theory. 2017 , 37, 1428-1440	77
76	Complications of Retinopathy of Prematurity Treatment. 2017 , 119-128	
75	Optic Nerve Head Histopathology in High Axial Myopia. 2017 , 26, 187-193	22
74	Axial Length and Anterior Segment Alterations in Former Preterm Infants and Full-Term Neonates Analyzed With Scheimpflug Imaging. 2017 , 36, 821-827	20
73	Retinopathy of Prematurity. 2017 ,	3

72	Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology. 2017 , 124, 619-633	76
71	Anatomical and refractive outcomes in patients with treated retinopathy of prematurity. 2017 , 92, 472-476	2
70	Anatomical and refractive outcomes in patients with treated retinopathy of prematurity. 2017 , 92, 472-476	
69	OUTCOMES AFTER LASER VERSUS COMBINED LASER AND BEVACIZUMAB TREATMENT FOR TYPE 1 RETINOPATHY OF PREMATUREITY IN ZONE I. 2017 , 37, 88-96	40
68	Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey. 2017 , 42, 462-469	39
67	Anti-Vascular Endothelial Growth Factor and the Evolving Management Paradigm for Retinopathy of Prematurity. 2018 , 7, 136-144	6
66	Retinopathy of prematurity: inflammation, choroidal degeneration, and novel promising therapeutic strategies. 2017 , 14, 165	70
65	Pathophysiology of Retinopathy of Prematurity. 2017 , 1681-1686.e2	
64	[Long-term effects of anti-VEGF therapy for retinopathy of prematurity]. 2018 , 115, 464-468	2
63	Supplemental Laser for Eyes Treated with Bevacizumab Monotherapy in Severe Retinopathy of Prematurity. 2018 , 2, 623-628	6
62	PROPHYLACTIC PERIPHERAL LASER AND FLUORESCEIN ANGIOGRAPHY AFTER BEVACIZUMAB FOR RETINOPATHY OF PREMATUREITY. 2018 , 38, 764-772	52
61	Pathophysiology, screening and treatment of ROP: A multi-disciplinary perspective. 2018 , 62, 77-119	60
60	Foveal Development in Infants Treated with Bevacizumab or Laser Photocoagulation for Retinopathy of Prematurity. 2018 , 125, 444-452	24
59	How Does the Standard of Care Evolve? Anti-Vascular Endothelial Growth Factor Agents in Retinopathy of Prematurity Treatment as an Example. 2018 , 125, 1485-1487	2
58	Foveal Depression and Related Factors in Patients with a History of Retinopathy of Prematurity. 2018 , 240, 106-110	4
57	Macular Structures, Optical Components, and Visual Acuity in Preschool Children after Intravitreal Bevacizumab or Laser Treatment. <i>American Journal of Ophthalmology</i> , 2018 , 192, 20-30	4.9 21
56	Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age. 2018 , 2018, 4565216	5
55	Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP). 2018 , 18, 19	22

54	12 Retinopathy of Prematurity. 2018 ,	
53	Update in myopia and treatment strategy of atropine use in myopia control. 2019 , 33, 3-13	65
52	Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP. 2019 , 23, 88.e1-88.e6	7
51	Neurodevelopmental Outcomes after Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity: A Prospective Case-Control Study. 2019 , 126, 1567-1577	28
50	[Epidemiology and anatomy of myopia]. 2019 , 116, 499-508	5
49	The use of bevacizumab in pediatric retinal and choroidal disease: A review. 2019 , 29, 338-347	6
48	Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review. 2019 , 14, e0225643	15
47	Myopia: Anatomic Changes and Consequences for Its Etiology. 2019 , 8, 355-359	31
46	Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression. 2019 , 39, 2267-2274	11
45	Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity. 2020 , 138, 14-20	3
44	Refractive error outcomes after intravitreal ranibizumab for retinopathy of prematurity. 2020 , 103, 495-500	
43	Refractive outcome of intravitreal bevacizumab injection in comparison to spontaneous regression of retinopathy of prematurity (ROP). 2020 , 28, 49-54	2
42	Different retinopathy of prematurity severity and outcomes in triplets: A case report. 2020 , 8, 2050313X20944306	
41	ANATOMICAL AND FUNCTIONAL RESULTS OF INTRAVITREAL AFLIBERCEPT MONOTHERAPY FOR TYPE 1 RETINOPATHY OF PREMATURITY: One-Year Outcomes. 2020 , 40, 2366-2372	4
40	Foveal microvasculature, refractive errors, optical biometry and their correlations in school-aged children with retinopathy of prematurity after intravitreal anti-vascular endothelial growth factors or laser photocoagulation. 2020 , 104, 691-696	5
39	Myopia: Ocular and Systemic Disease. 2021 , 409-422	
38	Theories of Myopization: Potential Role of a Posteriorly Expanding Bruch's Membrane. 2021 , 161-166	
37	Evaluation of the Effect of Different Treatment Management on Refractive Outcomes in Severe Retinopathy of Prematurity.. 2021 , 55, 545-550	0

36	Effects of diode laser photocoagulation treatment on ocular biometric parameters in premature infants with retinopathy of prematurity. 2021 , 14, 277-282	1
35	Refractive outcomes after intravitreal injection of anti-vascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis. 2021 , 11, e042384	0
34	Ranibizumab in retinopathy of prematurity - one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study. 2021 ,	1
33	Longitudinal Development of Refractive Error in Children Treated With Intravitreal Bevacizumab or Laser for Retinopathy of Prematurity. 2021 , 10, 14	0
32	Complications of retinopathy of prematurity treatment. 2021 , 32, 475-481	1
31	Myopia: Ocular and Systemic Disease. 2014 , 333-344	1
30	Retinopathy of Prematurity. 2016 , 21-29	1
29	Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a Meta-analysis. 2020 , 13, 806-815	6
28	Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years. 2015 , 52, 77-84	34
27	Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity. 2016 , 53, 375-382	4
26	The Characteristics and Short-term Refractive Error Outcomes of Cystoid Macular Edema in Premature Neonates as Detected by Spectral-Domain Optical Coherence Tomography. 2015 , 46, 806-12	6
25	Retinopathy of prematurity: a review of epidemiology and current treatment strategies. 2021 ,	3
24	Screening and Treatment in Retinopathy of Prematurity. 2015 , 112, 730-5	10
23	Retinopathy of Prematurity. 2016 , 1-38	
22	Effect of Anti-VEGF Intravitreal Injection on Emmetropization Process. 2016 , 4,	
21	Retinopathy of Prematurity. 2018 , 2349-2386	
20	Retinopathy of Prematurity. 2018 , 1-39	
19	Effect of two different doses of intravitreal bevacizumab with temporal retina-sparing laser photocoagulation for retinopathy of prematurity. 2018 , 11, 166-169	2

18	Lasercoagulation or Anti-VEGF: What Is the Better Treatment?. 2019 , 91-94	
17	The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review.. 2022 ,	0
16	Refractive and biometrical characteristics of children with retinopathy of prematurity who received laser photocoagulation or intravitreal ranibizumab injection.. 2022 ,	1
15	Factors associated with refractive outcome in children treated with bevacizumab for retinopathy of prematurity: the importance of retinal vascularization.. 2022 ,	0
14	Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes. 2022 ,	0
13	Refractive status, biometric components, and functional outcomes of patients with threshold retinopathy of prematurity: systemic review and a 17-year longitudinal study.	
12	Tamizaje y Tratamiento con Microdosis de Bevacizumab de Retinopatía del Prematuro en el Hospital Pedro de Bethancourth Antigua Guatemala. 18, 11-15	
11	Current concepts in the management of childhood myopia. 2022 , 70, 2800	0
10	Development of myopia in laser-treated ROP infants: prematurity or laser photocoagulation?.	0
9	Retinopathy of Prematurity. 2022 , 5-13	0
8	Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review.	0
7	One year follow-up of intravitreal bevacizumab injection in Aggressive Retinopathy of Prematurity at Indonesian national referral hospital: Case series. 2022 , 84, 104853	0
6	Outcomes of near confluent laser versus combined less dense laser and bevacizumab treatment of prethreshold ROP Type 1 Zone 2: a randomized controlled trial. 2022 , 22,	0
5	One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity.	0
4	Myopia: Histology, clinical features, and potential implications for the etiology of axial elongation. 2022 , 101156	2
3	Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity. 2023 ,	0
2	Current treatment of retinopathy of prematurity. 2017 , 456-461.e2	0
1	Investigating the factors affecting myopia in retinopathy of prematurity after laser treatment. 2023 , 9,	0

